DK2528946T3 - Fremgangsmåder til behandling af autoimmune sygdomme med dll4- antagonister - Google Patents
Fremgangsmåder til behandling af autoimmune sygdomme med dll4- antagonister Download PDFInfo
- Publication number
- DK2528946T3 DK2528946T3 DK11701933.1T DK11701933T DK2528946T3 DK 2528946 T3 DK2528946 T3 DK 2528946T3 DK 11701933 T DK11701933 T DK 11701933T DK 2528946 T3 DK2528946 T3 DK 2528946T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- dii4
- gly
- thr
- leu
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (7)
1. Delta-lignende ligand 4- (DII4) antagonist til anvendelse i forebyggelse, behandling eller bedring af multipel sklerose, hvor DII4-antagonisten er et antistof eller fragment deraf, der specifikt binder human DII4 (hDII4) og blokerer DII4-Notch-signalveje, og antagonisten blokereren interaktion mellem DII4 og Notch-receptor, hvorved antallet af Treg-celler øges og den multiple sklerose forebygges, behandles eller bedres, og hvor antistoffet eller fragmentet deraf omfatter en variabel tung kædereg ion (HCVR), der omfatter tungkæde CDR1-, CDR2- og CDR3-sekvenser af henholdsvis SEQ ID NO: 22, 24 og 26, og en variabel letkæ-deregion (LCVR), der omfatter letkæde CDR1-, CDR2- og CDR3-sekvenser af henholdsvis SEQ ID NO: 30, 32 og 34.
2. DII4-antagonist til anvendelse ifølge krav 1, hvor: (i) antistoffet eller fragmentet deraf omfatter en HCVR-sekvens af SEQ ID NO: 20 eller SEQ ID NO: 116; og (ii) antistoffet eller fragmentet deraf omfatter en LCVR-sekvens af SEQ ID NO: 28 eller SEQ ID NO: 118.
3. DII4-antagonist til anvendelse ifølge krav 1 eller 2, hvor antistoffet eller fragmentet deraf omfatter en HCVR/LCVR-kombination af SEQ ID NO: 20/28 eller 116/118.
4. DII4-antagonist til anvendelse ifølge et hvilket som helst af de foregående krav i kombination med mindst ét supplerende terapeutisk middel udvalgt fra et immunosuppressivt, anti-inflammatorisk middel og smertestillende middel, eventuelt hvor: (i) det supplerende terapeutiske middel er mindst ét udvalgt fra glucokortiko-ider, cyclosporin, methotrexat, ikke-steroide anti-inflammatoriske lægemidler (NSAID’er), TNF-a-antagonister, IL-1-antagonister, IL-6-antagonister og opioi-der; eller (ii) DII4-antagonisten og mindst ét supplerende terapeutisk middel er til samtidig eller sekventiel administration.
5. Anvendelse af en delta-lignende ligand 4- (DII4) antagonist i fremstillingen af et medikament til forebyggelse, behandling eller bedring af multipel sklerose, hvor DII4-antagonisten er et antistof eller fragment deraf, der specifikt binder human DII4 (hDII4) og blokerer DII4-Notch-signalveje, og antagonisten blokerer en interaktion mellem DII4 og Notch-receptor, hvorved antallet af Treg-celler øges og den multiple sklerose forebygges, behandles eller bedres, og hvor antistoffet eller fragmentet deraf omfatter en variabel tungkæderegion (HCVR), der omfatter tungkæde CDR1-, CDR2- og CDR3-sekvenser af henholdsvis SEQ ID NO: 22, 24 og 26, og en variabel letkæderegion (LCVR), der omfatter letkæde CDR1-, CDR2-og CDR3- sekvenser af henholdsvis SEQ ID NO: 30, 32 og 34.
6. Anvendelse ifølge krav 5, hvor: (i) antistoffet eller fragmentet deraf omfatter en HCVR-sekvens af SEQ ID NO: 20 eller SEQ ID NO: 116; og (ii) antistoffet eller fragmentet deraf omfatter en LCVR-sekvens af SEQ ID NO: 28 eller SEQ ID NO: 118.
7. Anvendelse ifølge krav 5 eller 6, hvor antistoffet eller fragmentet deraf omfatter en HCVR/LCVR-kombination af SEQ ID NO: 20/28 eller 116/118.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29980110P | 2010-01-29 | 2010-01-29 | |
| US36168710P | 2010-07-06 | 2010-07-06 | |
| US38869710P | 2010-10-01 | 2010-10-01 | |
| PCT/US2011/022810 WO2011094465A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2528946T3 true DK2528946T3 (da) | 2017-02-20 |
Family
ID=43925413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11701933.1T DK2528946T3 (da) | 2010-01-29 | 2011-01-28 | Fremgangsmåder til behandling af autoimmune sygdomme med dll4- antagonister |
| DK11701735.0T DK2528945T3 (da) | 2010-01-29 | 2011-01-28 | Fremgangsmåder til behandling af diabetes med dll4-antagonister |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11701735.0T DK2528945T3 (da) | 2010-01-29 | 2011-01-28 | Fremgangsmåder til behandling af diabetes med dll4-antagonister |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8889133B2 (da) |
| EP (2) | EP2528945B1 (da) |
| JP (2) | JP5883801B2 (da) |
| KR (2) | KR101797918B1 (da) |
| CN (2) | CN102884081A (da) |
| AR (1) | AR080026A1 (da) |
| AU (2) | AU2011210773B2 (da) |
| BR (2) | BR112012018820A8 (da) |
| CA (2) | CA2787394C (da) |
| CY (2) | CY1118223T1 (da) |
| DK (2) | DK2528946T3 (da) |
| ES (2) | ES2609663T3 (da) |
| HR (2) | HRP20170130T1 (da) |
| HU (2) | HUE031432T2 (da) |
| IL (2) | IL220889A (da) |
| JO (2) | JO3183B1 (da) |
| LT (2) | LT2528946T (da) |
| MX (2) | MX343555B (da) |
| MY (2) | MY156538A (da) |
| PL (2) | PL2528945T3 (da) |
| PT (2) | PT2528945T (da) |
| RS (2) | RS55595B1 (da) |
| RU (2) | RU2587624C2 (da) |
| SG (4) | SG182527A1 (da) |
| SI (2) | SI2528945T1 (da) |
| SM (2) | SMT201600412B (da) |
| TW (2) | TWI600433B (da) |
| UY (1) | UY33206A (da) |
| WO (2) | WO2011094467A2 (da) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| MX2012002605A (es) | 2009-08-29 | 2012-04-02 | Abbott Lab | Proteinas terapeutico de union a dll4. |
| HUE029661T2 (en) | 2009-10-16 | 2017-03-28 | Oncomed Pharm Inc | A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| BR112012021941A2 (pt) | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| ES2707580T3 (es) | 2011-09-23 | 2019-04-04 | Oncomed Pharm Inc | Agentes de unión a VEGF/DLL4 y usos de los mismos |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| SG11201503412RA (en) | 2012-11-01 | 2015-05-28 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| PL3020731T3 (pl) | 2013-07-09 | 2019-11-29 | Ablbio | Nowe podwójnie nakierowane białko specyficznie wiążące się z dll4 i vegf oraz zastosowanie tego białka |
| JP6560200B2 (ja) * | 2013-10-17 | 2019-08-14 | ザ ジェネラル ホスピタル コーポレイション | 自己免疫疾患の治療に応答性の対象を同定する方法およびそれを治療するための組成物 |
| US10413605B2 (en) * | 2014-04-08 | 2019-09-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Combination therapy for the treatment of autoimmune diseases |
| JP6827415B2 (ja) | 2014-10-31 | 2021-02-10 | メレオ バイオファーマ ５ インコーポレイテッド | 疾患の処置のための併用療法 |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| BR112021010336A2 (pt) * | 2018-11-29 | 2021-08-24 | Debora Zucco Sassi Yonezawa Siviglia | Método para tratar ou prevenir convulsões associadas a um distúrbio epiléptico |
| WO2022210802A1 (ja) * | 2021-03-30 | 2022-10-06 | 国立大学法人熊本大学 | 筋萎縮症治療剤 |
| WO2023159166A1 (en) * | 2022-02-18 | 2023-08-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| EP2332540A1 (en) * | 2002-05-21 | 2011-06-15 | Cv Therapeutics, Inc. | Administration of ranolazine for the treatment of diabetes |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| NZ568739A (en) | 2005-12-16 | 2010-09-30 | Regeneron Pharma | Therapeutic methods for inhibiting tumor growth with delta-like ligand 4 antagonists |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| SG175615A1 (en) * | 2006-06-06 | 2011-11-28 | Genentech Inc | Anti-dll4 antibodies and methods using same |
| EP2029159A2 (en) | 2006-06-06 | 2009-03-04 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| SI2054082T1 (sl) * | 2006-08-07 | 2013-04-30 | Regeneron Pharmaceuticals, Inc. | Uporaba DII4 antagonistov pri ishemični poškodbi ali vaskularni insuficienci |
| EP3357932A1 (en) | 2006-09-29 | 2018-08-08 | OncoMed Pharmaceuticals, Inc. | Compositions and methods for diagnosing and treating cancer |
| RU2448979C2 (ru) * | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| MX2012002605A (es) | 2009-08-29 | 2012-04-02 | Abbott Lab | Proteinas terapeutico de union a dll4. |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
-
2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/en active Application Filing
- 2011-01-28 CA CA2787394A patent/CA2787394C/en active Active
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/da active
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/da active
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/en active Application Filing
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 CA CA2787615A patent/CA2787615C/en active Active
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko active IP Right Grant
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko active IP Right Grant
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/en active Active
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/en active Active
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
-
2012
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
-
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
-
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
-
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-01-26 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2017-02-16 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2528946T3 (da) | Fremgangsmåder til behandling af autoimmune sygdomme med dll4- antagonister | |
| KR101781786B1 (ko) | 사람 안지오포이에틴-2에 대한 고 친화성 사람 항체 | |
| KR101842570B1 (ko) | 사람 안지오포이에틴-유사 단백질 4에 대한 사람 항체 | |
| KR20150023387A (ko) | 항-ｅｇｆｒ 항체 및 이의 용도 | |
| KR20140014067A (ko) | 항-cd48 항체 및 그의 용도 | |
| KR20200128125A (ko) | 신체 조성을 변경하기 위한 방법 |